These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23397357)

  • 21. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.
    Ged Y; Chen YB; Knezevic A; Casuscelli J; Redzematovic A; DiNatale RG; Carlo MI; Lee CH; Feldman DR; Patil S; Hakimi AA; Russo P; Motzer RJ; Voss MH
    Clin Genitourin Cancer; 2019 Jun; 17(3):e678-e688. PubMed ID: 31036466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.
    Kunene V; Miscoria M; Pirrie S; Islam MR; Afshar M; Porfiri E
    Clin Genitourin Cancer; 2014 Aug; 12(4):251-5. PubMed ID: 24560086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
    Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
    Haas NB; Lin X; Manola J; Pins M; Liu G; McDermott D; Nanus D; Heath E; Wilding G; Dutcher J
    Med Oncol; 2012 Jun; 29(2):761-7. PubMed ID: 21298497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
    Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
    BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.
    Mian BM; Bhadkamkar N; Slaton JW; Pisters PW; Daliani D; Swanson DA; Pisters LL
    J Urol; 2002 Jan; 167(1):65-70. PubMed ID: 11743277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathobiology and prognosis of chromophobe renal cell carcinoma.
    Klatte T; Han KR; Said JW; Böhm M; Allhoff EP; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Urol Oncol; 2008; 26(6):604-9. PubMed ID: 18367104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
    Richey SL; Culp SH; Jonasch E; Corn PG; Pagliaro LC; Tamboli P; Patel KK; Matin SF; Wood CG; Tannir NM
    Ann Oncol; 2011 May; 22(5):1048-1053. PubMed ID: 21115604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
    Shuch B; Said J; La Rochelle JC; Zhou Y; Li G; Klatte T; Kabbinaavar FF; Pantuck AJ; Belldegrun AS
    J Urol; 2009 Nov; 182(5):2164-71. PubMed ID: 19758641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
    Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
    Cheville JC; Lohse CM; Zincke H; Weaver AL; Leibovich BC; Frank I; Blute ML
    Am J Surg Pathol; 2004 Apr; 28(4):435-41. PubMed ID: 15087662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
    Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
    Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.